{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:24:24Z","timestamp":1787927064606,"version":"build-2784847793"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["407940_206504"],"award-info":[{"award-number":["407940_206504"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:p>\n                    Salvinorin A, the principal psychoactive constituent of\n                    <jats:italic toggle=\"yes\">Salvia divinorum<\/jats:italic>\n                    , is a highly selective \u03ba-opioid receptor agonist and a rare example of a \u03ba-opioid receptor-mediated psychedelic drug. Preclinical work of salvinorin A has shown promising effects in neuropsychiatric animal models. However, human studies remain heterogeneous and fragmented, highlighting the need for synthesis. Thus, we conducted a systematic review to synthesize available human studies of salvinorin A, with a focus on pharmacokinetics, pharmacodynamics, safety, and longer-term effects. We searched PubMed, Web of Science, and EMBASE from inception to January 18, 2026. We included 12 clinical trials comprising 174 participants. Most studies enrolled medically healthy, hallucinogen-experienced volunteers and administered salvinorin A by inhalation (0.375\u201321\u2009\u00b5g\/kg or 0.2\u201312\u2009mg). Pharmacokinetic profiles were characterized by rapid onset within seconds, peak effects at 1\u20132\u2009minutes, and resolution within 30\u2009minutes, consistent with fast absorption and clearance. Sublingual administration in two studies produced slower onset and longer duration, whereas oral dosing was inactive in one study. No serious adverse events were reported. Physiological parameters were largely stable, with occasional mild increases in blood pressure\/heart rate. Acute psychological effects included disorientation, anxiety, and distress in subsets of participants, alongside reports of positive subjective changes. Long-term adverse effects were rare, and abuse potential appeared low. Overall, salvinorin A exhibits a distinct human neuropsychopharmacological profile compared with serotonergic psychedelics. These findings support cautious further investigation in controlled studies. Further, salvinorin A can serve as a model for probing \u03ba-opioid receptor-mediated alterations of consciousness in humans.\n                  <\/jats:p>","DOI":"10.1177\/02698811261473385","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:59:51Z","timestamp":1787644791000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Salvinorin A in humans: A systematic review of pharmacokinetics, pharmacodynamics, and safety"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8111-3553","authenticated-orcid":false,"given":"Wolfgang Emanuel","family":"Z\u00fcrrer","sequence":"first","affiliation":[{"name":"Center for Reproducible Science and Research Synthesis, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Liesner","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Br\u00fcschweiler","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-7086","authenticated-orcid":false,"given":"Helena D.","family":"Aicher","sequence":"additional","affiliation":[{"name":"Neuroscience Center Zurich, University of Zurich and ETH Zurich, Switzerland"},{"name":"Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich and University of Zurich, Switzerland"},{"name":"Department of Psychiatry, University of Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Scheidegger","sequence":"additional","affiliation":[{"name":"Neuroscience Center Zurich, University of Zurich and ETH Zurich, Switzerland"},{"name":"Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich and University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1362-4819","authenticated-orcid":false,"given":"Benjamin Victor","family":"Ineichen","sequence":"additional","affiliation":[{"name":"Center for Reproducible Science and Research Synthesis, University of Zurich, Switzerland"},{"name":"Department of Clinical Research, University of Bern, Switzerland"},{"name":"Neuroscience Center Zurich, University of Zurich and ETH Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"crossref","unstructured":"Addy PH (2012) Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology 220(1): 195\u2013204. https:\/\/doi.org\/10.1007\/s00213-011-2470-6","DOI":"10.1007\/s00213-011-2470-6"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Addy PH Garcia-Romeu A Metzger M et al. (2015) The subjective experience of acute experimentally-induced Salvia divinorum inebriation. Journal of Psychopharmacology 29(4): 426\u2013435. https:\/\/doi.org\/10.1177\/0269881115570081","DOI":"10.1177\/0269881115570081"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Barker SA (2022) Administration of N N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT. Psychopharmacology 239(6): 1749\u20131763. https:\/\/doi.org\/10.1007\/s00213-022-06065-0","DOI":"10.1007\/s00213-022-06065-0"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Carhart-Harris R Nutt D (2017) Serotonin and brain function: A tale of two receptors. Journal of Psychopharmacology 31(9): 1091\u20131120. https:\/\/doi.org\/10.1177\/0269881117725915","DOI":"10.1177\/0269881117725915"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Carlezon WA B\u00e9guin C DiNieri JA et al. (2006) Depressive-like effects of the \u03ba-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. The Journal of Pharmacology and Experimental Therapeutics 316(1): 440\u2013447. https:\/\/doi.org\/10.1124\/jpet.105.092304","DOI":"10.1124\/jpet.105.092304"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Clay KJ Shenvi RA (2024) The original caretakers of salvinorin A and recognizing Indigenous contributions to science. Nature Chemistry 16(11): 1735\u20131736. https:\/\/doi.org\/10.1038\/s41557-024-01659-x","DOI":"10.1038\/s41557-024-01659-x"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Cumpston M Li T Page MJ et al. (2019) Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database of Systematic Reviews 10(10): ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142","DOI":"10.1002\/14651858.ED000142"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Doss MK May DG Johnson MW et al. (2020) The acute effects of the atypical dissociative hallucinogen salvinorin A on functional connectivity in the human brain. Scientific Reports 10(1): 16392. https:\/\/doi.org\/10.1038\/s41598-020-73216-8","DOI":"10.1038\/s41598-020-73216-8"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"E-Wen McCulloch D Liechti ME Kuypers KPC et al. (2024) Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects. Neuroscience Applied 3: 103938. https:\/\/doi.org\/10.1016\/j.nsa.2024.103938","DOI":"10.1016\/j.nsa.2024.103938"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Good M Joel Z Benway T et al. (2023) Pharmacokinetics of N N-dimethyltryptamine in Humans. European Journal of Drug Metabolism and Pharmacokinetics 48(3): 311\u2013327. https:\/\/doi.org\/10.1007\/s13318-023-00822-y","DOI":"10.1007\/s13318-023-00822-y"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Grundmann O Phipps S Zadezensky I et al. (2007) Salvia divinorum and Salvinorin A: An update on pharmacology and analytical methodology. Planta Medica 73(10): 1039\u20131046. https:\/\/doi.org\/10.1055\/s-2007-981566","DOI":"10.1055\/s-2007-981566"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Hooker JM Munro TA B\u00e9guin C et al. (2009a) Salvinorin A and derivatives: Protection from metabolism does not prolong short-term whole-brain residence. Neuropharmacology 57(4): 386\u2013391. https:\/\/doi.org\/10.1016\/j.neuropharm.2009.06.044","DOI":"10.1016\/j.neuropharm.2009.06.044"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Hooker JM Patel V Kothari S et al. (2009b) Metabolic changes in the rodent brain after acute administration of salvinorin A. Molecular Imaging and Biology 11(3): 137\u2013143. https:\/\/doi.org\/10.1007\/s11307-008-0192-x","DOI":"10.1007\/s11307-008-0192-x"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Hooker JM Xu Y Schiffer W et al. (2008) Pharmacokinetics of the potent hallucinogen salvinorin A in primates parallels the rapid onset and short duration of effects in humans. NeuroImage 41(3): 1044\u20131050. https:\/\/doi.org\/10.1016\/j.neuroimage.2008.03.003","DOI":"10.1016\/j.neuroimage.2008.03.003"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Johnson MW MacLean KA Caspers MJ et al. (2016) Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. Journal of Psychopharmacology 30(4): 323\u2013329. https:\/\/doi.org\/10.1177\/0269881116629125","DOI":"10.1177\/0269881116629125"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Johnson MW MacLean KA Reissig CJ et al. (2011) Human psychopharmacology and dose-effects of salvinorin A a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug and Alcohol Dependence 115(1\u20132): 150\u2013155. https:\/\/doi.org\/10.1016\/j.drugalcdep.2010.11.005","DOI":"10.1016\/j.drugalcdep.2010.11.005"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"Joseph C Renyu L Hoang VL (2022) Therapeutic potential of salvinorin A and its analogues in various neurological disorders. Translational Perioperative and Pain Medicine 9(2): 452\u2013457. https:\/\/doi.org\/10.31480\/2330-4871\/158","DOI":"10.31480\/2330-4871\/158"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Kivell B Prisinzano TE (2010) Kappa opioids and the modulation of pain. Psychopharmacology 210(2): 109\u2013119. https:\/\/doi.org\/10.1007\/s00213-010-1819-6","DOI":"10.1007\/s00213-010-1819-6"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Krystal JH Kavalali ET Monteggia LM (2024) Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology 49(1): 41\u201350. https:\/\/doi.org\/10.1038\/s41386-023-01629-w","DOI":"10.1038\/s41386-023-01629-w"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"Ley L Holze F Arikci D et al. (2023) Comparative acute effects of mescaline lysergic acid diethylamide and psilocybin in a randomized double-blind placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology 48(11): 1659\u20131667. https:\/\/doi.org\/10.1038\/s41386-023-01607-2","DOI":"10.1038\/s41386-023-01607-2"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"MacLean KA Johnson MW Reissig CJ et al. (2013) Dose-related effects of salvinorin A in humans: Dissociative hallucinogenic and memory effects. Psychopharmacology 226(2): 381\u2013392. https:\/\/doi.org\/10.1007\/s00213-012-2912-9","DOI":"10.1007\/s00213-012-2912-9"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Maqueda AE Valle M Addy PH et al. (2015) Salvinorin-A induces intense dissociative effects blocking external sensory perception and modulating interoception and sense of body ownership in humans. International Journal of Neuropsychopharmacology 18(12): pyv065. https:\/\/doi.org\/10.1093\/ijnp\/pyv065","DOI":"10.1093\/ijnp\/pyv065"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","unstructured":"Maqueda AE Valle M Addy PH et al. (2016) Naltrexone but not ketanserin antagonizes the subjective cardiovascular and neuroendocrine effects of Salvinorin-A in humans. International Journal of Neuropsychopharmacology 19(7): pyw016. https:\/\/doi.org\/10.1093\/ijnp\/pyw016","DOI":"10.1093\/ijnp\/pyw016"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Mendelson JE Coyle JR Lopez JC et al. (2011) Lack of effect of sublingual salvinorin A a naturally occurring kappa opioid in humans: A placebo-controlled trial. Psychopharmacology 214(4): 933\u2013939. https:\/\/doi.org\/10.1007\/s00213-010-2103-5","DOI":"10.1007\/s00213-010-2103-5"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Nichols DE (2016) Psychedelics. Pharmacological Reviews 68(2): 264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478","DOI":"10.1124\/pr.115.011478"},{"key":"e_1_3_3_27_1","doi-asserted-by":"crossref","unstructured":"Nichols DE Johnson M Nichols C (2017) Psychedelics as medicines: An emerging new paradigm. Clinical Pharmacology & Therapeutics 101(2): 209\u2013219. https:\/\/doi.org\/10.1002\/cpt.557","DOI":"10.1002\/cpt.557"},{"key":"e_1_3_3_28_1","doi-asserted-by":"crossref","unstructured":"Ona G Sampedro F Romero S et al. (2022) The kappa opioid receptor and the sleep of reason: Cortico-subcortical imbalance following Salvinorin-A. International Journal of Neuropsychopharmacology 25(1): 54\u201363. https:\/\/doi.org\/10.1093\/ijnp\/pyab063","DOI":"10.1093\/ijnp\/pyab063"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"Ortega A Blount JF Manchand PS (1982) Salvinorin a new trans-neoclerodane diterpene from Salvia divinorum (Labiatae). Journal of the Chemical Society Perkin Transactions 1: 2505. https:\/\/doi.org\/10.1039\/p19820002505","DOI":"10.1039\/p19820002505"},{"key":"e_1_3_3_30_1","doi-asserted-by":"crossref","unstructured":"Ouzzani M Hammady H Fedorowicz Z et al. (2016) Rayyan\u2014A web and mobile app for systematic reviews. Systematic Reviews 5(1): 210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_3_3_31_1","doi-asserted-by":"crossref","unstructured":"Page MJ McKenzie JE Bossuyt PM et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372: n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_3_32_1","doi-asserted-by":"crossref","unstructured":"Prisinzano TE (2005) Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sciences 78(5): 527\u2013531. https:\/\/doi.org\/10.1016\/j.lfs.2005.09.008","DOI":"10.1016\/j.lfs.2005.09.008"},{"key":"e_1_3_3_33_1","doi-asserted-by":"crossref","unstructured":"Prisinzano TE Rothman RB (2008) Salvinorin A analogs as probes in opioid pharmacology. Chemical Reviews 108(5): 1732\u20131743. https:\/\/doi.org\/10.1021\/cr0782269","DOI":"10.1021\/cr0782269"},{"key":"e_1_3_3_34_1","doi-asserted-by":"crossref","unstructured":"Ramaekers JG Reckweg JT Mason NL (2025) Benefits and challenges of ultra-fast short-acting psychedelics in the treatment of depression. American Journal of Psychiatry 182(1): 33\u201346. https:\/\/doi.org\/10.1176\/appi.ajp.20230890","DOI":"10.1176\/appi.ajp.20230890"},{"key":"e_1_3_3_35_1","doi-asserted-by":"crossref","unstructured":"Ranganathan M Schnakenberg A Skosnik PD et al. (2012). Dose-related behavioral subjective endocrine and psychophysiological effects of the \u03ba opioid agonist salvinorin A in humans. Biological Psychiatry 72(10): 871\u2013879. https:\/\/doi.org\/10.1016\/j.biopsych.2012.06.012","DOI":"10.1016\/j.biopsych.2012.06.012"},{"key":"e_1_3_3_36_1","doi-asserted-by":"crossref","unstructured":"Reiff CM Richman EE Nemeroff CB et al. (2020) Psychedelics and psychedelic-assisted psychotherapy. American Journal of Psychiatry 177(5): 391\u2013410. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19010035","DOI":"10.1176\/appi.ajp.2019.19010035"},{"key":"e_1_3_3_37_1","doi-asserted-by":"crossref","unstructured":"Schmidt MD Schmidt MS Butelman ER et al. (2005) Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse 58(3): 208\u2013210. https:\/\/doi.org\/10.1002\/syn.20191","DOI":"10.1002\/syn.20191"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","unstructured":"Siebert DJ (1994) Salvia divinorum and salvinorin A: New pharmacologic findings. Journal of Ethnopharmacology 43(1): 53\u201356. https:\/\/doi.org\/10.1016\/0378-8741(94)90116-3","DOI":"10.1016\/0378-8741(94)90116-3"},{"key":"e_1_3_3_39_1","doi-asserted-by":"crossref","unstructured":"Studerus E Gamma A Kometer M et al. (2012) Prediction of psilocybin response in healthy volunteers. PLoS ONE 7(2): e30800. https:\/\/doi.org\/10.1371\/journal.pone.0030800","DOI":"10.1371\/journal.pone.0030800"},{"key":"e_1_3_3_40_1","doi-asserted-by":"crossref","unstructured":"Teksin ZS Lee IJ Nemieboka NN et al. (2009) Evaluation of the transport in vitro metabolism and pharmacokinetics of Salvinorin A a potent hallucinogen. European Journal of Pharmaceutics and Biopharmaceutics 72(2): 471\u2013477. https:\/\/doi.org\/10.1016\/j.ejpb.2009.01.002","DOI":"10.1016\/j.ejpb.2009.01.002"},{"key":"e_1_3_3_41_1","doi-asserted-by":"crossref","unstructured":"Vuong C Van Uum SHM O\u2019Dell LE et al. (2010) The effects of opioids and opioid analogs on animal and human endocrine systems. Endocrine Reviews 31(1): 98\u2013132. https:\/\/doi.org\/10.1210\/er.2009-0009","DOI":"10.1210\/er.2009-0009"},{"key":"e_1_3_3_42_1","volume-title":"Drug, Set, and Setting: The Basis for Controlled Intoxicant Use","author":"Zinberg NE","year":"1984","unstructured":"Zinberg NE (1984) Drug, Set, and Setting: The Basis for Controlled Intoxicant Use, vol. 7. Yale University Press."},{"key":"e_1_3_3_43_1","doi-asserted-by":"crossref","unstructured":"Z\u00fcrrer WE Wettstein L Aicher HD et al. (2025) The translational potential of salvinorin A: Systematic review and meta-analysis of preclinical studies. Translational Psychiatry 15(1): 401. https:\/\/doi.org\/10.1038\/s41398-025-03638-3","DOI":"10.1038\/s41398-025-03638-3"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261473385","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261473385","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261473385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:32:41Z","timestamp":1787923961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261473385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":42,"alternative-id":["10.1177\/02698811261473385"],"URL":"https:\/\/doi.org\/10.1177\/02698811261473385","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"02698811261473385"}}